BioSpace News Archive

P4 Diagnostix®, a network of nationally recognized laboratories (“P4"), will be partnering with Pierian, a global leader in advanced clinical genomics technology and services, to launch somatic testing for prostate cancer patients.

Castor today announced the appointment of Andrew Sadler as Chief Product & Technology Officer (CPTO).

Azura Ophthalmics Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study protocol of AZR-MD-001 in Meibomian Gland Dysfunction (MGD).

Transcat, Inc. announced that it has purchased all of the capital stock of privately-held Galium Limited, effective September 28, 2022.

CIONIC, the innovative bionic clothing company behind the breakthrough Cionic Neural Sleeve, announced a $12.5M Series A financing.

Visus Therapeutics Inc. today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics.

CinRx Pharma announced today the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109. CIN-109 is a novel, long-acting first-in-class growth differentiation factor 15 (GDF-15) analog being developed as a treatment for obesity.

Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Thermo Scientific™ DynaSpin™ Single-Use Centrifuge system at the BioProcess International annual conference in Boston, MA.

Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that the European Medicines Agency (EMA) has released its final favorable qualification opinion providing a regulatory framework for the application of the company’s TwinRCT™ solution in Phase 2 and 3 clinical trials.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company’s September 6, 2022, public offering of securities.